ABCAM PLC-SPON ADR (ABCM)       15.25  +0.57 (+3.88%)

15.25  +0.57 (+3.88%)

US0003802040 - ADR - After market: 15.25 0 (0%)


Fundamental Rating

Overall ABCM gets a fundamental rating of 5 out of 10. We evaluated ABCM against 643 industry peers in the Biotechnology industry. Both the profitability and the financial health of ABCM get a neutral evaluation. Nothing too spectacular is happening here. ABCM is valued quite expensive, but it does show an excellent growth.




Profitability

Profitability Rating


ABCM's Return On Assets of 0.40% is amongst the best returns of the industry. ABCM outperforms 92% of its industry peers. The industry average Return On Assets is -39.49%.
ABCM has a Profit Margin of 1.24%. This is amongst the best returns in the industry. The industry average is -433.79%. ABCM outperforms 87% of its industry peers.

The Piotroski-F score of ABCM is 6.00. This is a neutral score and indicates average health and profitability for ABCM.
ABCM's Return On Equity of 0.59% is worse than the rest of the industry. The industry average Return On Equity is 20.47%. 100% of the industry peers have a better Return On Equity.
VS Industry

ROA (0.4%) VS Industry: 92% outperformed.

-1,226.49
115.38

ROE (0.59%) VS Industry: 0% outperformed.

0.59
826.08

Profit Margin (1.24%) VS Industry: 87% outperformed.

-436,406.25
5,207.39

Valuation

Valuation Rating


The low PEG Ratio, which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
With a price book ratio of 4.38, ABCM is valued correctly.
The Price/Earnings Ratio is 38.13, which means the current valuation is very expensive for ABCM.
Compared to an average industry Price/Earning Ratio of 17.00, ABCM is valued slightly more expensive.

With a Forward Price/Earnings Ratio of 44.08, ABCM is valued very expensively.
Compared to an average industry price book ratio of 1.95, ABCM is valued more expensive than its industry peers. 80% of the companies listed in the same industry are valued cheaper.
When comparing the Enterprise Value to EBITDA ratio of ABCM to the average industry ratio of 0.78, ABCM is valued more expensive than its industry peers. 96% of the companies listed in the same industry are valued cheaper.
VS Industry

Price/Earnings (38.13) VS Industry: 21% outperformed.

549.40
0.92

Price/Book (4.38) VS Industry: 20% outperformed.

649.31
0.07

Enterprise Value/ EBITDA (33.39) VS Industry: 4% outperformed.

4,910.81
0.00

Growth

Growth Rating


ABCM shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 97.92%, which is quite impressive.
The Earnings Per Share is expected to grow by 39.84% on average over the next 5 years. This is a very strong growth
The EPS growth is accelerating: in the next 5 years the growth will be better than in the last years.
Looking at the last year, ABCM shows a quite strong growth in Revenue. The Revenue has grown by 17.12% in the last year.

Measured over the past 5 years, ABCM shows a very strong growth in Revenue. The Revenue has been growing by 21.94% on average per year.
Based on estimates for the next 5 years, ABCM will show a quite strong growth in Revenue. The Revenue will grow by 13.95% on average per year.
Measured over the past 5 years, ABCM shows a decrease in Earnings Per Share. The EPS has been decreasing by -3.43% on average per year.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming 5 years, we see that the growth is decreasing.

PastFuture
5Y3Y1Y1Y2Y3Y5Y
EPS-3.43% -13.29% 97.92% 112.62% 65.12% 50.69% 39.84%
Revenue21.94% 25.68% 17.12% 21.91% 17.29% 15.81% 13.95%

Health

Health Rating


An Altman-Z score of 6.01 indicates that ABCM is not in any danger for bankruptcy at the moment.
When comparing the Altman-Z score to an average industry score of 0.65, ABCM is in better financial health than the average industry peer.
A Current Ratio of 1.13 indicates that ABCM should not have too much problems paying its short term obligations.
The Piotroski-F score of ABCM is 6.00. This is a neutral score and indicates average health and profitability for ABCM.

When comparing the Current Ratio of ABCM to the average industry Current Ratio of 6.90, ABCM is less able to pay its short term obligations than its industry peers. 96% of its industry peers have a better Current Ratio.
ABCM has a Quick Ratio of 1.13. This is a bad value and indicates that ABCM is not financially healthy enough and could expect problems in meeting its short term obligations.
When comparing the Quick Ratio of ABCM to the average industry Current Ratio of 6.89, ABCM is less able to pay its short term obligations than its industry peers. 97% of its industry peers have a better Quick Ratio.
Compared to an average industry Debt to Equity Ratio of 0.00, ABCM is requires more financing than its industry peers. 80% of its industry peers have a better Debt to Equity Ratio.
VS Industry

Debt/Equity (0.15) VS Industry: 20% outperformed.

20.91
-18.60

Quick Ratio (0.82) VS Industry: 3% outperformed.

0.04
141.63

Current Ratio (1.13) VS Industry: 4% outperformed.

0.15
141.63

Altman-Z (6.01) VS Industry: 74% outperformed.

-257.46
1,422.64

Dividend

Dividend Rating


ABCM has a yearly dividend return of 0.30%, which is pretty low.
Compared to an average industry Dividend Yield of 3.16, ABCM's dividend is way lower than its industry peers. On top of this 100% of the companies listed in the same industry pay a better dividend than ABCM!

With a Dividend Yield of 0.30, ABCM pays less dividend than the S&P500 average, which is at 2.39.
ABCM is new to the dividend game and has less than 3 years of track record.
VS Industry

Dividend Yield (0.3%) VS Industry: 0% outperformed.

0.30
4.80
ABCM Daily chart

ABCAM PLC-SPON ADR15.25

NASDAQ:ABCM (8/10/2022, 7:00:00 PM)+0.57 (+3.88%)

After market: 15.25 0 (0%)

Chartmill FA Rating
GICS Sector Health Care
GICS IndustryGroup Pharmaceuticals, Biotechnology & Life Sciences
GICS Industry Biotechnology
Earnings (Last) 07-20 2022-07-20/bmo Earnings (Next) N/A N/A
Ins Owners N/A Inst Owners 10.69%
Market Cap 3.49B Analysts 76.47
Valuation
PE 38.13 Fwd PE 44.08
PEG (NY) 0.34 PEG (5Y) N/A
P/S 9.12 P/B 4.38
EV/EBITDA 33.39
Profitability
ROA 0.4% ROE 0.59%
PM 1.24 Asset Turnover 0.32
Growth
EPS 1Y 97.92% EPS 3Y -13.29%
EPS 5Y -3.43% EPS growth Q2Q 679.48%
EPS Next Y 112.62% EPS Next 2Y 65.12%
EPS Next 3Y 50.69% EPS Next 5Y 39.84%
Revenue growth 1Y 17.12% Revenue growth 3Y 25.68%
Revenue growth 5Y 21.94% Revenue growth Q2Q 12%
Revenue Next Year 21.91% Revenue Next 2Y 17.29%
Revenue Next 3Y 15.81% Revenue Next 5Y 13.95%
Health
Current Ratio 1.13 Quick Ratio 0.82
Altman-Z 6.01 F-Score 6
Debt/Equity 0.15
Dividend
Dividend Yield 0.3% Dividend Growth N/A
DP 0% Ex-Date N/A

Fundamental Stock Screener Links

Screen Image

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Screen Image

Growth Stock Screener

Find more growth stocks the USA

Screen Image

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Screen Image

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Screen Image

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA